Indication intelligence, analysis and sector perception

Vericel (VCEL) proposes 5 M share $65 M offering at $13.00

May 31, 2018 10:20pm

VCEL closed at $13.45 (down -$0.50) $13.95 and was down -$0.05 to $13.95 on Wednesday considering Tuesday's $14.00

It’s about time, ATM over-dependence has been a detriment to the share’s pricing

Shares outstanding = 36.68 M with a float of 29.14 M

That is still a "lucky hit" of -7.6% - considering this market

VCEL intends to offer and sell 5 M shares of its common stock in a public offering. - up from 3.75 M

Vericel also intends to grant the underwriters a 30-day option to purchase up to an overallottment of 750 K shares (was 562.5 K

Leerink Partners is acting as the lead book runner for the offering. BTIG, LLC is also acting as a book runner and a new wrinkle - Ladenburg Thalman is acting as co-manager

It's about time, 1/2/18, the stock was priced at $5.90 and the short position has decreased -

The offering price is now ... $13.00T

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 55 min ago
RegMed Investors (RMi) Closing Bell: this week’s trend is an admission that the sector is without pricing sustainability suppressing a value directional

10 hours 57 min ago
RegMed Investors’ (RMi) pre-open: the down draft doesn’t seem to be over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.